Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Change in Accured Expenses of -$753000.0 for Q2 2026, down 360.55% year-over-year from $289000.0 in Q2 2025, and down 165.08% quarter-over-quarter from $1.2 million in Q1 2026.
Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Champions Oncology's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$753000.0 for Q2 2026.
- In Q2 2026, Change in Accured Expenses fell 360.55% year-over-year to -$753000.0; the TTM figure through Apr 2026 stood at $37000.0 (down 90.63% YoY), while the FY2026 annual figure was $37000.0, down 90.63% from the prior year.
- Change in Accured Expenses for Q2 2026 stood at -$753000.0, down from $1.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $1.2 million in Q1 2026, with the low at -$755000.0 in Q3 2025.
- The 5-year median for Change in Accured Expenses is $73500.0 (2022), against an average of $37833.3.
- The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses sank 1098.41% in 2025, then soared 3515.62% in 2026.
- Champions Oncology's Change in Accured Expenses stood at -$287000.0 in 2022, then jumped by 76.66% to -$67000.0 in 2023, then surged by 304.48% to $137000.0 in 2024, then jumped by 183.21% to $388000.0 in 2025, then slumped by 294.07% to -$753000.0 in 2026.
- Business Quant data shows CSBR's Change in Accured Expenses at -$753000.0 in Q2 2026, $1.2 million in Q1 2026, and $388000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -753,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -753,000.00 |
| Apr 30, 2026 | -753,000.00 |
| Jan 31, 2026 | 1.16 Mn |
| Jan 31, 2026 | 1.16 Mn |
| Oct 31, 2025 | 388,000.00 |
| Oct 31, 2025 | 388,000.00 |
| Jul 31, 2025 | -755,000.00 |
| Jul 31, 2025 | -755,000.00 |
| Apr 30, 2025 | 289,000.00 |
| Apr 30, 2025 | 289,000.00 |
| Jan 31, 2025 | 32,000.00 |
| Jan 31, 2025 | 32,000.00 |
| Oct 31, 2024 | 137,000.00 |
| Oct 31, 2024 | 137,000.00 |
| Jul 31, 2024 | -63,000.00 |
| Jul 31, 2024 | -63,000.00 |
| Apr 30, 2024 | -269,000.00 |
| Apr 30, 2024 | -269,000.00 |
| Jan 31, 2024 | 405,000.00 |
| Jan 31, 2024 | 405,000.00 |